Gyre Therapeutics (GYRE) Competitors $9.76 +0.19 (+1.99%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. OGN, MRUS, CRNX, SWTX, AKRO, VKTX, XENE, CPRX, MOR, and PTGXShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Organon & Co. (OGN), Merus (MRUS), Crinetics Pharmaceuticals (CRNX), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Organon & Co. Merus Crinetics Pharmaceuticals SpringWorks Therapeutics Akero Therapeutics Viking Therapeutics Xenon Pharmaceuticals Catalyst Pharmaceuticals MorphoSys Protagonist Therapeutics Gyre Therapeutics (NASDAQ:GYRE) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do insiders and institutionals hold more shares of GYRE or OGN? 24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 19.5% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 1.4% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, GYRE or OGN? Gyre Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Does the MarketBeat Community favor GYRE or OGN? Organon & Co. received 17 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesOrganon & Co.Outperform Votes1833.33% Underperform Votes3666.67% Does the media prefer GYRE or OGN? In the previous week, Organon & Co. had 9 more articles in the media than Gyre Therapeutics. MarketBeat recorded 11 mentions for Organon & Co. and 2 mentions for Gyre Therapeutics. Organon & Co.'s average media sentiment score of 1.06 beat Gyre Therapeutics' score of 0.94 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts rate GYRE or OGN? Organon & Co. has a consensus target price of $19.75, suggesting a potential upside of 52.63%. Given Organon & Co.'s higher probable upside, analysts plainly believe Organon & Co. is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Organon & Co. 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33 Which has higher earnings and valuation, GYRE or OGN? Organon & Co. has higher revenue and earnings than Gyre Therapeutics. Organon & Co. is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M8.65-$92.93M$0.05195.20Organon & Co.$6.40B0.53$864M$3.333.89 Is GYRE or OGN more profitable? Organon & Co. has a net margin of 13.49% compared to Gyre Therapeutics' net margin of -84.57%. Organon & Co.'s return on equity of 431.62% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% Organon & Co. 13.49%431.62%8.03% SummaryOrganon & Co. beats Gyre Therapeutics on 12 of the 18 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$914.93M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio195.207.4422.4818.48Price / Sales8.65242.70395.10103.59Price / Cash50.4965.8538.1834.62Price / Book54.226.516.774.25Net Income-$92.93M$143.21M$3.22B$248.23M7 Day Performance7.02%1.98%1.50%0.89%1 Month Performance52.26%6.89%4.01%3.53%1 Year Performance-29.58%-2.52%16.16%5.08% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.0864 of 5 stars$9.76+2.0%N/A-37.4%$914.93M$105.76M195.2040Upcoming EarningsOGNOrganon & Co.4.77 of 5 stars$12.73+4.3%$20.60+61.8%-30.5%$3.28B$6.40B3.8210,000Positive NewsMRUSMerus3.4423 of 5 stars$45.28+3.9%$85.31+88.4%+1.3%$3.13B$36.13M-11.4637Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionPositive NewsCRNXCrinetics Pharmaceuticals3.6693 of 5 stars$33.11+2.2%$73.00+120.5%-23.8%$3.08B$1.04M-8.88210Upcoming EarningsNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.9536 of 5 stars$46.18+3.3%$63.17+36.8%-0.8%$2.93B$191.59M-13.27230Analyst ForecastNews CoverageHigh Trading VolumeAKROAkero Therapeutics3.7928 of 5 stars$42.17+2.9%$76.29+80.9%+129.3%$2.92BN/A-11.2530Insider TradeNews CoveragePositive NewsVKTXViking Therapeutics4.482 of 5 stars$25.94+3.8%$87.15+236.0%-63.7%$2.91BN/A-25.9420Analyst ForecastOptions VolumeAnalyst RevisionXENEXenon Pharmaceuticals2.603 of 5 stars$37.84+0.6%$56.78+50.0%-6.0%$2.90B$9.43M-13.42210Upcoming EarningsOptions VolumePositive NewsCPRXCatalyst Pharmaceuticals4.6886 of 5 stars$23.63+0.8%$32.29+36.6%+61.4%$2.88B$491.73M20.0380Upcoming EarningsNews CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.4338 of 5 stars$44.39-0.2%$65.44+47.4%+82.5%$2.72B$434.43M16.69120Upcoming EarningsPositive News Related Companies and Tools Related Companies Organon & Co. Competitors Merus Competitors Crinetics Pharmaceuticals Competitors SpringWorks Therapeutics Competitors Akero Therapeutics Competitors Viking Therapeutics Competitors Xenon Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors MorphoSys Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GYRE Stock Free GYRE Stock Alerts